| Budget Amount *help |
¥138,600,000 (Direct Cost: ¥138,600,000)
Fiscal Year 2009: ¥27,500,000 (Direct Cost: ¥27,500,000)
Fiscal Year 2008: ¥27,500,000 (Direct Cost: ¥27,500,000)
Fiscal Year 2007: ¥27,500,000 (Direct Cost: ¥27,500,000)
Fiscal Year 2006: ¥27,500,000 (Direct Cost: ¥27,500,000)
Fiscal Year 2005: ¥28,600,000 (Direct Cost: ¥28,600,000)
|
|---|
| Research Abstract |
We have been developed the new monoclonal antibody against FGFR-1, which express on human hepatocellular carcinoma and induced by IFN. When we administrate this antibody and IFN simultaneously, strong anti-cancer effect was observed in vitro and in vivo. Furthermore, we have been developed other monoclonal antibodies aimed at therapy for gastric cancer. These are the humanized bispecific monoclonal antibody targeted tumor antigen×CD3 and the humanized trifunctional bispecific antibody which have the Fc region.
|
